Oral Health-Related Complications of Breast Cancer Treatment: Assessing Dental Hygienists' Knowledge and Professional Practice

References

1. ↵
   1. Jemal A,
   2. Siegel R,
   3. Xu J,
   4. Ward E

   . Cancer statistics, 2010. CA Cancer J Clin. 2010; 60(5): 277-300.

   OpenUrlCrossRefPubMedWeb of Science
2. ↵
   1. National Cancer Institute

   . Breast cancer statistics. 2011. [Internet] 2013 [cited 2013 January 28]. Available from: http://www.cancer.gov/cancertopics/types/breast
3. ↵
   1. McPherson K,
   2. Steel CM,
   3. Dixon JM

   . ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ. 2000; 321(7261): 624-628.

   OpenUrlFREE Full Text
4. ↵
   1. National Comprehensive Cancer Network

   . Practice Guidelines in Oncology. Invasive breast cancer. [Internet] January 2010.[cited 2012 January 28]. Available from: http://www.nccn.org/patients/patient_guidelines/breast/index.html#/2/ {this link doesn't work} --- http://www.nccn.org/patients/guidelines/breast/index.html
5. ↵
   1. Carlson RW,
   2. Moench S,
   3. Hurria A,
   4. et al

   . NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 (4): S1-S25.

   OpenUrl
6. ↵
   1. Bedard PL,
   2. Cardoso F

   . Can some patients avoid adjuvant chemotherapy for early-stage breast cancer? Nat Rev Clin Oncol. 2011; 8(5): 272-279.

   OpenUrlCrossRefPubMed
7. ↵
   1. EBCTCG

   . Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472): 1687-1717.

   OpenUrlCrossRefPubMedWeb of Science
8. ↵
   1. Piccart-Gebhart MJ

   . Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: what we know and what we still need to learn. Eur J Cancer. 2006; 42(12): 1715-1719.

   OpenUrlCrossRefPubMedWeb of Science
9. ↵
   1. Harvey JM,
   2. Clark GM,
   3. Osborne CK,
   4. Allred DC

   . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5): 1474-1481.

   OpenUrlAbstract/FREE Full Text
10. ↵
    1. Rastelli F,
    2. Crispino S

    . Factors predictive of response to hormone therapy in breast cancer. Tumori. 2008; 94(3): 370-383.

    OpenUrlPubMedWeb of Science
11. ↵
    1. Miller WR,
    2. O'Neill J

    . The importance of local synthesis of estrogen within the breast. Steroids. 1987; 50(4-6): 537-548.

    OpenUrlCrossRefPubMed
12. ↵
    1. Burstein HJ,
    2. Griggs JJ

    . Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010; 19(3): 639-647.

    OpenUrlPubMed
13. ↵
    1. Korde LA,
    2. Zujewski JA,
    3. Kamin L,
    4. et al

    . Multidisciplinary meeting on male breast cancer: summary and research recommendations. J Clin Oncol. 2010; 28(12): 2114-2122.

    OpenUrlAbstract/FREE Full Text
14. ↵
    1. National Institutes of Health

    : Oral Complications of Cancer Therapies: Diagnosis, Prevention and Treatment Consensus Statement [Internet] 1989. [cited 2012 October 14]. Available from: http://consensus.nih.gov/1989/1989OralComplicationsCancerTherapy073html.htm.
15. 1. Epstein JB,
    2. Parker IR,
    3. Epstein MS,
    4. Stevenson-Moore P

    . Cancer-related oral health care services and resources: a survey of oral and dental care in Canadian cancer centres. J Can Dent Assoc. 2004; 70(5): 302-304.

    OpenUrlPubMed
16. ↵
    1. Sheiham A,
    2. Steele JG,
    3. Marcenes W,
    4. Finch S,
    5. Walls AW

    . The impact of oral health on stated ability to eat certain foods; findings from the National Diet and Nutrition Survey of Older People in Great Britain. Gerodontology. 1999; 16(1): 11-20.

    OpenUrlCrossRefPubMed
17. ↵
    1. Sonis ST

    . Oral mucositis in cancer therapy. J Support Oncol. 2004; 2(6 Suppl 3): 3-8.

    OpenUrlPubMed
18. 1. Raber-Durlacher JE,
    2. Elad S,
    3. Barasch A

    . Oral mucositis. Oral Oncol. 2010; 46(6): 452-456.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Sadler GR,
    2. Stoudt A,
    3. Fullerton JT,
    4. Oberle-Edwards LK,
    5. Nguyen Q,
    6. Epstein JB

    . Managing the oral sequelae of cancer therapy. Medsurg Nurs. 2003; 12(1): 28-36.

    OpenUrlPubMed
20. ↵
    1. Almazrooa SA,
    2. Woo SB

    . Bisphosphonate and non-bisphosphonate-associated osteonecrosis of the jaw: a review. J Am Dent Assoc. 2009; 140(7): 864-875.

    OpenUrlAbstract/FREE Full Text
21. ↵
    1. Raber-Durlacher JE,
    2. Barasch A,
    3. Peterson DE,
    4. Lalla RV,
    5. Schubert MM,
    6. Fibbe WE

    . Oral complications and management considerations in patients treated with high-dose chemotherapy. Support Cancer Ther. 2004; 1(4): 219-229.

    OpenUrlPubMed
22. 1. Watters AL,
    2. Epstein JB,
    3. Agulnik M

    . Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47(6): 441-448.

    OpenUrlCrossRefPubMed
23. 1. McCarthy GM,
    2. Skillings JR

    . Orofacial complications of chemotherapy for breast cancer. Oral Surg Oral Med Oral Pathol. 1992; 74(2): 172-178.

    OpenUrlPubMed
24. ↵
    1. Ohrn KE,
    2. Wahlin YB,
    3. Sjoden PO

    . Oral status during radiotherapy and chemotherapy: a descriptive study of patient experiences and the occurrence of oral complications. Support Care Cancer. 2001; 9(4): 247-257.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Shapiro CL,
    2. Manola J,
    3. Leboff M

    . Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. J Clin Oncol. 2001; 19(14): 3306-3311.

    OpenUrlAbstract/FREE Full Text
26. 1. Cameron DA,
    2. Douglas S,
    3. Brown JE,
    4. Anderson RA

    . Bone mineral density loss during adjuvant chemotherapy in pre-menopausal women with early breast cancer: is it dependent on oestrogen deficiency? Breast Cancer Res Treat. 2010; 123(3): 805-814.

    OpenUrlCrossRefPubMed
27. ↵
    1. Weinstein RS

    . Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med. 2011; 365(1): 62-70.

    OpenUrlCrossRefPubMedWeb of Science
28. ↵
    1. Hadji P,
    2. Ziller M,
    3. Maskow C,
    4. Albert U,
    5. Kalder M

    . The influence of chemotherapy on bone mineral density, quantitative ultrasonometry and bone turnover in pre-menopausal women with breast cancer. Eur J Cancer. 2009; 45(18): 3205-3212.

    OpenUrlCrossRefPubMedWeb of Science
29. ↵
    1. Robinson WR,
    2. Luck M,
    3. Omar H,
    4. Blades N,
    5. Morris K,
    6. Coscia J

    . A pilot study of bone density loss in menopausal women treated with chemotherapy for cancer. Support Care Cancer. 2005; 13(8): 663-667.

    OpenUrlPubMed
30. ↵
    1. Vehmanen L,
    2. Saarto T,
    3. Elomaa I,
    4. Makela P,
    5. Valimaki M,
    6. Blomqvist C

    . Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. Eur J Cancer. 2001; 37(18): 2373-2378.

    OpenUrlCrossRefPubMedWeb of Science
31. ↵
    1. Khan MN,
    2. Khan AA

    . Cancer treatment-related bone loss: a review and synthesis of the literature. Curr Oncol. 2008; 15(1): S30-40.

    OpenUrlCrossRefPubMed
32. ↵
    1. Mincey BA,
    2. Duh MS,
    3. Thomas SK,
    4. et al

    . Risk of cancer treatment-associated bone loss and fractures among women with breast cancer receiving aromatase inhibitors. Clin Breast Cancer. 2006; 7(2): 127-132.

    OpenUrlPubMed
33. ↵
    1. Gralow JR,
    2. Biermann JS,
    3. Farooki A,
    4. et al

    . NCCN Task Force Report: Bone Health in Cancer Care. J Natl Compr Canc Netw. 2009; 7(3): S1-S32.

    OpenUrl
34. ↵
    1. Wardrop RW,
    2. Hailes J,
    3. Burger H,
    4. Reade PC

    . Oral discomfort at menopause. Oral Surg Oral Med Oral Pathol. 1989; 67(5): 535-540.

    OpenUrlCrossRefPubMed
35. ↵
    1. Forabosco A,
    2. Criscuolo M,
    3. Coukos G,
    4. et al

    . Efficacy of hormone replacement therapy in postmenopausal women with oral discomfort. Oral Surg Oral Med Oral Pathol. 1992; 73(5): 570-574.

    OpenUrlCrossRefPubMedWeb of Science
36. ↵
    1. Taichman LS,
    2. Havens AM,
    3. Van Poznak CH

    . Potential implications of adjuvant endocrine therapy for the oral health of postmenopausal women with breast cancer. Breast Cancer Res Treat. 2013; 137(1): 23-32.

    OpenUrlPubMed
37. ↵
    1. Draper C

    . Cancer Prevention and Treatment: The Dental Hygienist's role. American Dental Hygienist's Association. Access. 2010:26-31.
38. ↵
    NIH Consensus Statement Online: Oral complications of cancer Therapies: Diagnosis, Prevention, and Treatment. Conn Med. 1989; 53(10): 595-601.

    OpenUrlPubMed
39. 1. National Institute of Dental and Craniofacial Research

    . Cancer Treatment and You: Three Good Reasons to See a Dentist BEFORE Cancer Treatment. [Internet] 2011. [cited 2012 December 14]. Available from: http://www.nidcr.nih.gov/NR/rdonlyres/4FB39055-1788-4A9E-ADE6-FFBF-2C1B6FE9/0/ThreeGoodReasons.pdf
40. ↵
    1. National Institute of Dental and Craniofacial Research

    . Oral complications of cancer treatment: What the Oncology team can do. [Internet] 2008 [cited 2012 December 28] Available from: http://www.nidcr.nih.gov/OralHealth/Topics/Cancer-Treatment/oralcomplicationscanceroncology.htm.
41. ↵
    1. National Institute of Dental and Craniofacial Research

    . Oral complications of cancer treatment: What the Dental team can do. [Internet] 2008 [cited 2012 January 28] Available from: http://www.nidcr.nih.gov/OralHealth/Topics/Cancer-Treatment/OralComplicationsCancerOral.htm.
42. ↵
    1. Baddour LM,
    2. Bettmann MA,
    3. Bolger AF,
    4. et al

    . Non-valvular cardiovascular device-related infections. Circulation. 2003; 108(16): 2015-2031.

    OpenUrlFREE Full Text
43. ↵
    1. Hong CH,
    2. Allred R,
    3. Napenas JJ,
    4. Brennan MT,
    5. Baddour LM,
    6. Lockhart PB

    . Antibiotic prophylaxis for dental procedures to prevent indwelling venous catheter-related infections. Am J Med. 2010; 123(12): 1128-1133.

    OpenUrlPubMed
44. ↵
    1. Hayes S,
    2. Cornish B,
    3. Newman B

    . Comparison of methods to diagnose lymphoedema among breast cancer survivors: 6-month follow-up. Breast Cancer Res Treat. 2005; 89(3): 221-226.

    OpenUrlCrossRefPubMedWeb of Science
45. 1. Harris SR,
    2. Hugi MR,
    3. Olivotto IA,
    4. Levine M

    . Clinical practice guidelines for the care and treatment of breast cancer: 11. Lymphedema. CMAJ. 2001; 164(2): 191-199.

    OpenUrlAbstract/FREE Full Text
46. ↵
    1. McLaughlin SA

    . Lymphedema: separating fact from fiction. Oncology. 2012; 26(3): 242-249.

    OpenUrlPubMed
47. ↵
    1. Epstein JB,
    2. Parker IR,
    3. Epstein MS,
    4. Gupta A,
    5. Kutis S,
    6. Witkowski DM

    . A survey of National Cancer Institute-designated comprehensive cancer centers' oral health supportive care practices and resources in the USA. Support Care Cancer. 2007; 15(4): 357-362.

    OpenUrlPubMed
48. ↵
    1. McGuire DB

    . Barriers and strategies in implementation of oral care standards for cancer patients. Support Care Cancer. 2003; 11(7): 435-441.

    OpenUrlCrossRefPubMedWeb of Science
49. ↵
    1. Jones JA,
    2. Avritscher EB,
    3. Cooksley CD,
    4. Michelet M,
    5. Bekele BN,
    6. Elting LS

    . Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006; 14(6): 505-515.

    OpenUrlCrossRefPubMedWeb of Science
50. ↵
    1. Howlader N,
    2. Noone AM,
    3. Neyman N,
    4. et al

    . SEER Cancer Statistics Review, 1975-2008. Bethesda, MD, National Cancer Institute. [Internet]. November 2010 [cited 2012 October 12]. Available from: http://seer.cancer.gov/csr/1975_2008/
51. ↵
    1. Burstein HJ,
    2. Prestrud AA,
    3. Seidenfeld J,
    4. et al

    . American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010; 28(23): 3784-3796.

    OpenUrlAbstract/FREE Full Text
52. ↵
    1. Mamounas EP,
    2. Jeong JH,
    3. Wickerham DL,
    4. et al

    . Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008; 26(12): 1965-1971.

    OpenUrlAbstract/FREE Full Text
53. ↵
    1. Henry NL,
    2. Giles JT,
    3. Stearns V

    . Aromatase inhibitor-associated musculoskeletal symptoms: etiology and strategies for management. Oncology. 2008; 22(12): 1401-1408.

    OpenUrlPubMed
54. ↵
    1. Henry NL,
    2. Pchejetski D,
    3. A'Hern R,
    4. et al

    . Inflammatory cytokines and aromatase inhibitor-associated musculoskeletal syndrome: a case-control study. Br J Cancer. 2010; 103(3): 291-296.

    OpenUrlCrossRefPubMedWeb of Science
55. ↵
    1. Hong CH,
    2. Napenas JJ,
    3. Hodgson BD,
    4. Stokman MA,
    5. et al

    . A systematic review of dental disease in patients undergoing cancer therapy. Support Care Cancer. 2010; 18(8): 1007-1021.

    OpenUrlCrossRefPubMed
56. ↵
    1. Leimola-Virtanen R,
    2. Salo T,
    3. Toikkanen S,
    4. Pulkkinen J,
    5. Syrjanen S

    . Expression of estrogen receptor (ER) in oral mucosa and salivary glands. Maturitas. 2000; 36(2): 131-137.

    OpenUrlCrossRefPubMedWeb of Science
57. ↵
    1. Valimaa H,
    2. Savolainen S,
    3. Soukka T,
    4. et al

    . Estrogen receptor-beta is the predominant estrogen receptor subtype in human oral epithelium and salivary glands. J Endocrinol. 2004; 180(1): 55-62.

    OpenUrlAbstract
58. ↵
    1. Streckfus CF,
    2. Baur U,
    3. Brown LJ,
    4. Bacal C,
    5. Metter J,
    6. Nick T

    . Effects of estrogen status and aging on salivary flow rates in healthy Caucasian women. Gerontology. 1998; 44(1): 32-39.

    OpenUrlCrossRefPubMed
59. ↵
    1. Mott AE,
    2. Grushka M,
    3. Sessle BJ

    . Diagnosis and management of taste disorders and burning mouth syndrome. Dent Clin North Am. 1993; 37(1): 33-71.

    OpenUrlPubMed
60. 1. Lopez-Jornet P,
    2. Camacho-Alonso F,
    3. Andujar-Mateos P,
    4. Sanchez-Siles M,
    5. Gomez-Garcia F

    . Burning mouth syndrome: an update. Med Oral Patol Oral Cir Bucal. 2010; 15(4): e562-568.

    OpenUrlPubMed
61. 1. Ferris GM

    . Alteration in female sex hormones: their effect on oral tissues and dental treatment. Compendium. 1993; 14(12): 1558-1564, 1566.

    OpenUrlPubMed
62. ↵
    1. Zakrzewska JM

    . Women as dental patients: are there any gender differences? Int Dent J. 1996; 46(6): 548-557.

    OpenUrlPubMed
63. ↵
    1. Wactawski-Wende J

    . Periodontal diseases and osteoporosis: association and mechanisms. Ann Periodontol. 2001; 6(1): 197-208.

    OpenUrlCrossRefPubMed
64. ↵
    1. Wactawski-Wende J,
    2. Hausmann E,
    3. Hovey K,
    4. Trevisan M,
    5. Grossi S,
    6. Genco RJ

    . The association between osteoporosis and alveolar crestal height in postmenopausal women. J Periodontol. 2005; 76(11): 2116-2124.

    OpenUrlCrossRefPubMed